Elbit Systems Ltd. — FY2022 Form 20-F Summary
Business context and reporting period
This is an annual report for the fiscal year ended December 31, 2022, filed May 1, 2023, and prepared under U.S. GAAP in U.S. dollars. The filing is not a standalone 2022 fourth-quarter report; it does not provide a clear set of Q4-only results. Elbit develops and supplies defense, homeland-security and commercial-aviation systems, with most revenue from government-related customers. Beginning in 2022, it reported five segments—Aerospace, C4I and Cyber, ISTAR and EW, Land, and Elbit Systems of America (ESA)—and recast comparative segment data.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $5.512 billion | $5.279 billion |
| Gross profit / margin | $1.373 billion / 24.9% | $1.358 billion / 25.7% |
| Operating income / margin | $367.5 million / 6.7% | $418.5 million / 7.9% |
| Net income attributable to shareholders | $275.4 million | $274.4 million |
| Diluted EPS | $6.18 | $6.20 |
| Operating cash flow | $240.1 million | $416.9 million |
Revenue rose about 4%, while reported net income was nearly flat and operating income declined. Gross margin and operating margin contracted. Cash from operations fell, with working-capital movements including a $305 million inventory increase and a $123 million decrease in trade and other payables; higher customer advances and lower receivables provided offsets.
At year-end, cash and cash equivalents were $211.1 million, working capital was $754 million and the current ratio was 1.18. Borrowings included $391 million of bank loans and $483 million of Series B, C and D notes. The balance sheet reports total assets of $9.216 billion and total equity of $2.758 billion. The company said available cash, operating cash generation, credit lines and financing arrangements should meet needs for at least the next fiscal year.
Other notable balance-sheet and commitment figures: inventories were $1.946 billion, up from $1.670 billion; employee benefit liabilities were $618 million; bank and financial-institution guarantees were approximately $3.858 billion; purchase commitments were approximately $3.029 billion; and outstanding industrial participation/offset obligations were approximately $2.029 billion through 2030. Guarantees and commitments are not equivalent to funded debt.
Changes versus the prior comparable period
- Revenue growth was led by C4ISR systems, up to $1.611 billion from $1.372 billion, including higher UAS sales in Europe and stronger U.S. Sparton sales. Aerospace segment revenue rose 9%; C4I and Cyber rose 9%; Land rose 5%; ISTAR and EW rose 2%; ESA fell 2%.
- Geographically, Europe revenue increased to $1.244 billion from $885 million, while North America declined to $1.490 billion from $1.609 billion, mainly due to lower medical-instrumentation sales. Europe’s share of revenue increased from 16.8% to 22.6%.
- Operating income was pressured by higher employee compensation and unfavorable program mix. ESA’s operating income fell to $75.0 million from $124.3 million, reflecting lower COVID-related medical-instrumentation sales, supply-chain disruption and mix.
- Net financing expense increased to $51.4 million from $40.4 million, with management citing higher interest rates. Other expense was $23.6 million versus $5.3 million of other income in 2021.
- The effective tax rate was 8.2%, versus 34.3% in 2021. The prior-year tax expense included an approximately $80 million charge related to releasing Israeli exempt earnings; the 2022 provision benefited from adjustments following tax settlements in Israeli subsidiaries.
Outlook, management commentary and risks
Backlog was $15.118 billion at December 31, 2022, up from $13.661 billion a year earlier; 75% was for orders outside Israel. The company expected approximately 60% to be performed in 2023 and 2024. Management said the backlog is not necessarily indicative of future sales, and the filing provides no formal numerical revenue or earnings guidance.
Management cited opportunities from planned increases in European defense spending and demand for C4ISR, cyber, unmanned systems and advanced defense technologies. It also cautioned that the Russia-Ukraine conflict has contributed to supply-chain disruption, cost increases and market volatility, and that the full impact could not be assessed. Inflation, NIS/U.S. dollar movements, higher interest rates, component shortages and longer lead times may affect costs, particularly under fixed-price contracts.
Long-term contract accounting is a key uncertainty: FY2022 estimate-at-completion changes on significant contracts reduced cost of revenues by an unfavorable $38.0 million, net income by $32.7 million and diluted EPS by $0.73. These estimates can change as program costs, schedules and technical assumptions develop. A June 2022 ransomware incident at a U.S. subsidiary led to disclosure of certain personal data and a minimal amount of non-critical business data; the company said it was contained and had no material impact.
Other risks include dependence on government budgets and export approvals, customer cancellations or delayed payments, fixed-price cost overruns, supplier and talent constraints, acquisition integration, cyber threats, offset obligations, currency exposure, pension funding, and political and security conditions in Israel and the Middle East. A proposed Israeli order designating the company and most Israeli subsidiaries as defense entities had not been finalized; such designation could impose ownership, governance, operating and approval restrictions. Management reported material compliance with loan covenants in 2021 and 2022. The auditor issued an unqualified opinion on the financial statements and internal controls; management also concluded controls were effective, while ERP implementation continued in phases through 2023.
Most important facts for investors to verify
- Review the full audited statements and notes for cash-flow quality, inventory growth, customer advances, receivable collection and the composition and maturity of debt.
- Track contract estimates and loss provisions, especially the unfavorable FY2022 cumulative catch-up adjustments, and assess whether supply-chain inflation or execution risks cause further margin pressure.
- Assess backlog conversion, cancellation and funding conditions, including the timing of the expected 2023–2024 deliveries and the impact of government budgets and export licenses.
- Distinguish recurring operating performance from stock-price-linked compensation and unusual gains or grants. FY2022 included $62 million of phantom-plan compensation expense and substantial other operating income from asset and investment sales and a grant.
- Monitor the $3.858 billion of guarantees, $3.029 billion of purchase commitments, $2.029 billion of offset obligations, and the defined-benefit pension funding position; these are significant exposures alongside reported borrowings.